Crystalys Therapeutics

Chronic gout
#Clinical trial #Crystalys Therapeutics #Gout

Crystalys doses first patients in Phase II gout trial 

Crystalys Therapeutics has dosed the first patients in a Phase II trial evaluating a treatment for difficult-to-treat gout.  The trial will evaluate dotinurad, a next-generation, once daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety and efficacy for the treatment of gout, particularly in patients with limited treatment… Read More

#News